Is Xilio Therapeutics, Inc. (XLO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 20.9% / 30% | 142.0% / 30% | 0.0% / 30% | 22.13% / 5% | ✗ NOT HALAL |
| DJIM | 20.9% / 33% | 142.0% / 33% | 0.0% / 33% | 22.13% / 5% | ✗ NOT HALAL |
| MSCI | 11.5% / 33% | 77.8% / 33% | 0.0% / 33% | 22.13% / 5% | ✗ NOT HALAL |
| S&P | 20.9% / 33% | 142.0% / 33% | 0.0% / 33% | 22.13% / 5% | ✗ NOT HALAL |
| FTSE | 11.5% / 33% | 77.8% / 33% | 0.0% / 50% | 22.13% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -86.5% | |
| Net Margin | -80.1% | |
| Return on Equity (ROE) | -132.5% | |
| Return on Assets (ROA) | -23.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$18M |
| Free Cash Flow | -$18M |
| Total Debt | $8M |
| Debt-to-Equity | 19.7 |
| Current Ratio | 2.6 |
| Total Assets | $71M |
Price & Trading
| Last Close | $8.68 |
| 50-Day MA | $7.94 |
| 200-Day MA | $9.60 |
| Avg Volume | 36K |
| Beta | -0.0 |
|
52-Week Range
$6.47
| |
About Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Xilio Therapeutics, Inc. (XLO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Xilio Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Xilio Therapeutics, Inc.'s debt ratio?
Xilio Therapeutics, Inc.'s debt ratio is 20.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.5%.
What are Xilio Therapeutics, Inc.'s key financial metrics?
Xilio Therapeutics, Inc. has a market capitalization of $611M, and revenue of $6M. The company maintains a gross margin of 100.0% and a net margin of -80.1%. Return on equity stands at -132.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.